NeuroMetrix, Inc. (NURO)

Addition of Quell® Platform Broadens electroCore's Bioelectronic Technology Portfolio and Accelerates Growth in Chronic Pain and Wellness Markets Addition of Quell® Platform Broadens electroCore's Bioelectronic Technology Portfolio and Accelerates Growth in Chronic Pain and Wellness Markets

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of NeuroMetrix, Inc. (NasdaqCM: NURO) to electroCore, Inc. Under the terms of the proposed transaction, shareholders of NeuroMetrix will receive one non-tradeable contingent value right (the “CVR”) per share of NURO common stock owned. Each CVR will represent the right to receive (i) certain future net proceeds f.

NEW YORK , Dec. 18, 2024 /PRNewswire/ -- Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating NeuroMetrix, Inc. (NASDAQ: NURO ), relating to the proposed merger with electroCore, Inc. Under the terms of the agreement, shareholders of NeuroMetrix will be entitled to receive the equivalent of the balance of NeuroMetrix's net cash at the closing of the transaction, estimated to be $9 million in the aggregate.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of NeuroMetrix, Inc. (NASDAQ: NURO) to electroCore, Inc. is fair to NeuroMetrix shareholders. Halper Sadeh encourages NeuroMetrix shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether NeuroMetrix and its board of direct.

The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector

WOBURN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (“NeuroMetrix” or the “Company”) (Nasdaq: NURO) today announced it has entered into a definitive merger agreement whereby electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, will acquire NeuroMetrix.

Despite a 51% revenue dip, NURO narrowed losses in Q3 2024 by reducing operating expenses by 25%, offsetting the challenging revenue environment.

WOBURN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today for the purpose of clarity, reiterated that the Company is engaged in a review of strategic alternatives.

NeuroMetrix, Inc. (NASDAQ:NURO ) Q2 2024 Earnings Conference Call August 6, 2024 8:00 AM ET Company Participants Thomas Higgins - Senior Vice President and Chief Financial Officer Shai Gozani - Founder and Chief Executive Officer Conference Call Participants Jarrod Cohen - JM Cohen & Company Operator Good morning, and welcome to the NeuroMetrix Second Quarter 2024 Business and Financial Update. My name is Amy, and I will be your moderator on the call.

WOBURN, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2024 second quarter business and financial highlights before the opening of the market on August 6, 2024.

NeuroMetrix (NASDAQ:NURO – Get Free Report) and Sharps Technology (NASDAQ:STSS – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends. Profitability This table compares NeuroMetrix and Sharps Technology’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets NeuroMetrix -151.51% -39.85% -37.08% Sharps Technology N/A -102.25% -72.97% Valuation and Earnings This table compares NeuroMetrix and Sharps Technology’s revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroMetrix $5.90 million 1.38 -$6.53 million ($6.30) -0.64 Sharps Technology N/A N/A -$9.84 million N/A N/A NeuroMetrix has higher revenue and earnings than Sharps Technology. Analyst Recommendations This is a summary of current ratings for NeuroMetrix and Sharps Technology, as provided by MarketBeat.com. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroMetrix 0 0 0 0 N/A Sharps Technology 0 0 0 0 N/A Volatility & Risk NeuroMetrix has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500. Comparatively, Sharps Technology has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Insider & Institutional Ownership 19.4% of NeuroMetrix shares are owned by institutional investors. Comparatively, 17.2% of Sharps Technology shares are owned by institutional investors. 7.3% of NeuroMetrix shares are owned by company insiders. Comparatively, 14.1% of Sharps Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Summary NeuroMetrix beats Sharps Technology on 6 of the 8 factors compared between the two stocks. About NeuroMetrix (Get Free Report) NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts. About Sharps Technology (Get Free Report) Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.

WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2024.

Joshua S. Horowitz joins Board of Directors At-the-market equity facility terminated WOBURN, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders, Ephraim Fields of Echo Lake Capital.

WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck alone accurately detects diabetic peripheral neuropathy (DPN).

NeuroMetrix today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in Dec 2022.

NURO stock price has declined 99% since its IPO Gozani has received compensation of over $10 million since the IPO Gozani was charged by the FTC for various wrongdoings at NURO Gozani apparently personally paid the FTC $4 million as part of a settlement Gozani barely owns any NURO shares NURO continues to sell stock significantly below its net cash value NEW YORK, NY / ACCESSWIRE / March 12, 2024 / Earlier today Echo Lake Capital sent a letter to the Board of Directors of Neurometrix, Inc. (NASDAQ:NURO). The letter listed the top ten reasons why the Board should immediately fire Shai Gozani, the company's longstanding Chairman and CEO.